News Stories

Dec, 2021

Novartis announced that the U.S. Food and Drug Administration (FDA) approved Leqvio (inclisiran) as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of LDL-Cholesterol. Inclisiran is the first FDA-approved small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol.

0
No votes yet
Name: Top Stories
Sep, 2021

The National Lipid Association would like to extend its congratulations to all of our Fellows of the NLA, current and past, honored at the 2023 National Lipid Association Honors & Awards Ceremony earlier this month:

 

Cindy L. Bredefeld, DO, FNLA

Jaime Burkle, MD, FNLS

Joette Hughes, MSN, CRNP, CLS, FNLA

Sabyasachi Sen, MD, FNLA

0
No votes yet
Name: NLA News
Aug, 2021

The U.S. Food and Drug Administration released a Drug Safety Communication on July 20, 2021, concerning the removal of the strongest warning against using statins during pregnancy. The warning states that statins should never be used in any patients during pregnancy.

0
No votes yet
Name: Top Stories